[go: up one dir, main page]

ES2059729T5 - Preparado farmaceutico de liberacion controlada y metodo para producir el mismo. - Google Patents

Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.

Info

Publication number
ES2059729T5
ES2059729T5 ES89302767T ES89302767T ES2059729T5 ES 2059729 T5 ES2059729 T5 ES 2059729T5 ES 89302767 T ES89302767 T ES 89302767T ES 89302767 T ES89302767 T ES 89302767T ES 2059729 T5 ES2059729 T5 ES 2059729T5
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
produce
same
substance
controlled liberation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89302767T
Other languages
English (en)
Other versions
ES2059729T3 (es
Inventor
Masayoshi Samejima
Kazuo Noda
Yoshiyuki Hirakawa
Hiroyuki Yoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13722933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059729(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of ES2059729T3 publication Critical patent/ES2059729T3/es
Application granted granted Critical
Publication of ES2059729T5 publication Critical patent/ES2059729T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE EXPLICA UNA PREPARACION FARMACEUTICA DE LIBERACION SOSTENIDA, QUE COMPRENDE UN NUCLEO QUE CONTIENE EL PRINCIPIO ACTIVO FARMACEUTICO, Y UNA PELICULA POROSA DE UNA SUSTANCIA POLIMERICA HIDROFOBICA O UNA SUSTANCIA POLIMERICA HIDROBFOBICA Y UNA SUSTANCIA POLIMERICA HIDROFILICA, EL NUCLEO SE RECUBRE CON LA MEMBRANA POROSA. TAMBIEN SE EXPLICA EL METODO PARA SU OBTENCION.
ES89302767T 1988-03-31 1989-03-21 Preparado farmaceutico de liberacion controlada y metodo para producir el mismo. Expired - Lifetime ES2059729T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8060488 1988-03-31

Publications (2)

Publication Number Publication Date
ES2059729T3 ES2059729T3 (es) 1994-11-16
ES2059729T5 true ES2059729T5 (es) 2002-09-16

Family

ID=13722933

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89302767T Expired - Lifetime ES2059729T5 (es) 1988-03-31 1989-03-21 Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.

Country Status (21)

Country Link
US (1) US5068112A (es)
EP (1) EP0335560B2 (es)
KR (1) KR950007202B1 (es)
AT (1) ATE91888T1 (es)
AU (1) AU610711B2 (es)
BG (1) BG50712A3 (es)
CA (1) CA1339078C (es)
DE (1) DE68907762T3 (es)
DK (1) DK156289A (es)
ES (1) ES2059729T5 (es)
FI (1) FI101344B1 (es)
FR (1) FR2629344B1 (es)
HK (1) HK76195A (es)
HU (1) HU201882B (es)
IE (1) IE64348B1 (es)
IL (1) IL89695A0 (es)
NO (1) NO178136C (es)
PH (1) PH25791A (es)
PT (1) PT90153B (es)
RU (1) RU1836083C (es)
ZA (1) ZA892131B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101344B1 (fi) † 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US6350462B1 (en) * 1990-12-26 2002-02-26 Olympus Optical Co., Ltd. Hollow porous ceramic carrier for embedding in patient for sustained medicament release and method of preparation thereof
JP2538134B2 (ja) * 1991-04-08 1996-09-25 田辺製薬株式会社 徐放性製剤およびその製造法
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
ES2120354B1 (es) * 1996-02-12 1999-07-01 Univ Sevilla Dispositivo terapeutico para direccionar farmacos hacia el tramo del tracto gastrointestinal deseado en funcion de las caracteristicas fisicoquimicas del mismo.
DE19628776A1 (de) * 1996-07-17 1998-01-22 Bayer Ag Oral applizierbare Granulate von Hexahydropyrazinderivaten
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
BR9802915A (pt) * 1997-09-12 2000-01-11 Oscar Gold Procedimento para formar composições farmaceuticas em pilulas ou granulos substancialmente esfericos, de ação controlada e continuada, contendo como agente ativo o (7-bromo-1,3-diidro-5-(2-piridninilo)-2h-1,4-benzodiazep ina-2(1h)-um)
MY122499A (en) 1997-11-10 2006-04-29 Searle & Co Use of alkylated iminosugars to treat multidrug resistance
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
CA2362785A1 (en) 1999-02-12 2001-02-08 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
CA2362914C (en) * 1999-02-12 2009-04-14 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
KR100574213B1 (ko) * 2000-01-27 2006-04-27 다나베 세이야꾸 가부시키가이샤 서방성 제제 및 그의 제조 방법
US20050119310A1 (en) * 2000-02-14 2005-06-02 Mueller Richard A. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US20040208936A1 (en) * 2002-07-22 2004-10-21 Roland Chorin Novel compositions
EP1562552A1 (en) * 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
WO2004082679A1 (ja) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
EP1974726B1 (en) 2003-03-26 2010-01-13 Egalet A/S Matrix compositions for controlled delivery of drug substances
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
ES2272914T3 (es) * 2003-05-20 2007-05-01 Ethypharm Composicion farmaceutica oral de liberacion sostenida.
FR2855412B1 (fr) * 2003-05-27 2007-05-25 Menvielle Bourg Fabienn Joanny Composition a liberation prolongee de magnesium, et son application dans le domaine therapeutique, cosmetique et nutritionnel
WO2004112746A1 (en) * 2003-06-26 2004-12-29 Korea Research Institute Of Chemical Technology Controlled release-drug delivery system for oral administration
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
KR100615952B1 (ko) 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
ATE525065T1 (de) * 2006-07-10 2011-10-15 Pfleger R Chem Fab Pharmazeutische zubereitung für die orale verabreichung mit gesteuerter wirkstofffreisetzung im dünndarm und verfahren zu ihrer herstellung
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN105534936B (zh) 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
FR2931361B1 (fr) * 2008-05-20 2012-08-31 Menvielle Bourg Fabienne Joanny Systeme a base de magnesium et son utilisation en cosmetique
FR2931359B1 (fr) * 2008-05-20 2012-12-21 Menvielle Bourg Fabienne Joanny Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2223896A1 (de) † 1972-05-17 1973-11-29 Sanol Arznei Schwarz Gmbh Verfahren zum ueberziehen von feinteiligen arzneimitteln
DD146547A5 (de) † 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4377568A (en) † 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) † 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5989622A (ja) † 1983-09-29 1984-05-23 Furointo Sangyo Kk 公害を生じないフイルムコ−テング法
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DE3571924D1 (en) * 1984-04-11 1989-09-07 Thiemann Arzneimittel Gmbh Dosage units for controlled release of active material
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4663147A (en) * 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
US5254347A (en) † 1988-03-31 1993-10-19 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
FI101344B1 (fi) † 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta

Also Published As

Publication number Publication date
KR890014095A (ko) 1989-10-21
EP0335560A2 (en) 1989-10-04
PH25791A (es) 1991-11-05
NO891052D0 (no) 1989-03-13
NO178136C (no) 1996-01-31
EP0335560B1 (en) 1993-07-28
IE891006L (en) 1989-09-30
DK156289A (da) 1989-10-01
EP0335560A3 (en) 1990-12-27
KR950007202B1 (ko) 1995-07-04
DE68907762T3 (de) 2003-11-20
DE68907762D1 (de) 1993-09-02
US5068112A (en) 1991-11-26
FI101344B (fi) 1998-06-15
DK156289D0 (da) 1989-03-30
IL89695A0 (en) 1989-09-28
EP0335560B2 (en) 2002-01-23
BG50712A3 (bg) 1992-10-15
ES2059729T3 (es) 1994-11-16
DE68907762T2 (de) 1993-11-11
NO891052L (no) 1989-10-02
NO178136B (no) 1995-10-23
PT90153A (pt) 1989-11-10
IE64348B1 (en) 1995-07-26
AU3227389A (en) 1989-10-05
PT90153B (pt) 1994-07-29
ZA892131B (en) 1989-11-29
HUT50050A (en) 1989-12-28
FI891163L (fi) 1989-10-01
FR2629344A1 (fr) 1989-10-06
RU1836083C (ru) 1993-08-23
FI101344B1 (fi) 1998-06-15
FI891163A0 (fi) 1989-03-10
FR2629344B1 (fr) 1994-09-16
ATE91888T1 (de) 1993-08-15
AU610711B2 (en) 1991-05-23
HU201882B (en) 1991-01-28
CA1339078C (en) 1997-07-29
HK76195A (en) 1995-05-26

Similar Documents

Publication Publication Date Title
ES2059729T5 (es) Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.
DK618088A (da) Farmaceutisk doseringsform til kontrolleret afgivelse af aktivt stof
NO851170L (no) Lagringsstabile, hurtignedbrytende farmasoeytiske virksomme stoff-presslegemer
NL300007I1 (nl) Preparaat voor de gereguleerde afgifte van een werkzame stof.
ES557835A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
DE3685094D1 (de) Pharmazeutisches praeparat zur kontrollierten freisetzung von wirkstoffen.
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
ES2006457A4 (es) Un procedimiento para la preparacion de una formulacion farmaceutica.
NO871774L (no) Medikament-system med kontrollert frisettelse av det aktive middel.
DK0607118T3 (da) System til administrering af phospholipid
ES2060593T3 (es) Sistema de aporte de farmacos.
DE58909793D1 (de) Neue Benzopyran-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung sowie die Verbindungen enthaltenden Zubereitungen
DK653688A (da) Stabiliserede laegemiddelaktive forbindelser, fremgangsmaade til deres frmstilling samt stabile laegemiddelpraeparater
ES2060399T3 (es) Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento.
NO871044D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater.
FI91964C (fi) Menetelmä uusien, farmaseuttisesti aktiivisten 1-(hydroksistyryyli)-5H-2,3-bentsodiatsepiinijohdannaisten valmistamiseksi
NO893909L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
MX9301235A (es) DERIVADOS 1,4-DIOXINO(2,3-B)PIRIDINA. á
NO891114L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
DK160816C (da) Benzoyl-urinstof-derivater, fremgangsmaade til fremstilling af disse, fremgangsmaade til bekaempelse af insektangreb samt insekticidt middel indeholdende disse
SE8102732L (sv) Biologiskt aktiva blandningar eller kompositioner samt salter av heterocykliska foreningar
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO873514D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk aktive forbindelser.
IT7927443A0 (it) Metodo e dispositivo per la fabbricazione di corpi cavi cilindrici.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 335560

Country of ref document: ES